- Source : Press Release
- Date : 2020-11-05
- Event type : Phase 1
- Companies : NKMax
NKmax , Alzheimer's Clinical Phase 1 Cruise
NK Max ( KOSDAQ 182400) Alzheimer's patients in clinical Mexican first phase being a cruise .
NK Max is a clinical one Alzheimer's patient to participate in the 21 hit 3 after a patient registration , Super NK autoimmune cell therapy (SNK01) prior to administration PET-CT jungyirago forward five said one . The company after 12 goes the first week of January to the patient's blood and , 12 doses first patient in mid-May (First Injection) said they plan to .
Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects with Mild Cognitive Impairment(MCI) and Alzheimer's Disease(AD)
This clinical one phase the past 8 Mon IND completed and approved , cell therapy Mexican customs import and export permits for clinical trials (Material Transfer License) is completed by the state .
This clinical trial is conducted in 21 patients with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) . First, ▲ 9 persons to split into three groups SNK01 10 million , 20 million , 40 respectively million four maximum tolerated dose to dosing times (MTD; Maximum Tolerated Dose ) OK, and , after ▲ 12 for persons SNK01 of the maximum tolerated dose administration safety (safety), tolerance (tolerability) and potential efficacy (Exploratory efficacy) to evaluate .
NKmax America's vice president Paul Y. Song said, “ This clinical trial, led by Professor Ming Guo of UCLA School of Medicine, who is an authority on Alzheimer's research in the United States, is the largest hospital in Mexico, according to the recommendations of the US FDA . anghelreseu hospital (hospital Angeles Tijuana) progress is in , " said ," Alzheimer's is a 126 would predict, but there is no drug to prescribe to form a market size of $ 100 million . USA only five will be the only cure for Alzheimer's market, with more than one million patients , " he said .